Insight
Noncompete Enforceability: Evaluating Risk in a Bifurcated Regulatory Landscape
Pressure is building from two directions at once: a more targeted FTC enforcement posture and active litigation under M.G.L. c. 149, § 24L testing what counts as sufficient consideration in lieu of garden leave.
.webp)
This insight is provided for general informational purposes and does not constitute legal advice. Noncompete enforceability remains a fact-specific determination governed by federal standards and the Massachusetts Noncompetition Agreement Act, M.G.L. c. 149, § 24L. Organizations should consult Massachusetts employment counsel before revising restrictive covenant strategies or form agreements.
For many life sciences organizations, noncompete agreements have long been treated as fixed institutional infrastructure. That assumption is increasingly fragile. Pressure is mounting from two distinct directions: a recalibrated federal enforcement posture at the FTC and active litigation in Massachusetts testing a core ambiguity in the state’s noncompete statute. For founders and investors, this is a moment where institutional assumption should be replaced with proactive validation.
The federal landscape has shifted in method rather than intent. Following the vacatur of the nationwide noncompete rule, the FTC returned to its traditional enforcement path under Section 5 of the FTC Act, 15 U.S.C. § 45. The agency is now aggressively utilizing its authority to challenge restrictive covenants on a case-by-case basis, specifically targeting agreements it views as overbroad, role-agnostic, or untethered to legitimate protectable interests. This shift is particularly visible in the life sciences and healthcare sectors, where the FTC remains focused on labor mobility as a driver of competition.
While Section 5 authority remains subject to judicial and doctrinal limitations, the practical risk for employers is clear. Blanket noncompete templates applied uniformly across an entire workforce carry significantly higher scrutiny risk than they did two years ago. The federal focus has moved toward identifying restrictions that reach beyond what is necessary to protect trade secrets or sensitive confidential information. A restrictive covenant architecture that is calibrated to the specific role and its actual access to competitive assets is now the only defensible posture.
Simultaneously, Massachusetts is facing its own point of inflection. The Massachusetts Noncompetition Agreement Act, M.G.L. c. 149, § 24L, mandates that enforceability depends on providing either garden leave or other mutually agreed upon consideration. Garden leave is mathematically defined as at least 50 percent of the employee’s highest annualized base salary over the prior two years. The alternative, other mutually agreed upon consideration, is where the statute remains dangerously silent. It does not define a minimum value threshold or specify what qualifies as sufficient to support a post-employment restriction.
This ambiguity is being tested in a putative class action filed against Boston Beer Company in the United States District Court for the District of Massachusetts. The plaintiffs challenge the enforceability of noncompetes supported by a one-time $3,000 payment, arguing it was nominal relative to their compensation and insufficient under the statute. While a district court decision is not binding statewide, the case represents the first substantive judicial inquiry into whether nominal cash payments or equity grants satisfy the spirit of the law. For companies relying on small cash sign-ons or stock options as the sole consideration for a noncompete, the legal floor is moving.
Compliance with § 24L requires more than just adequate consideration. The statute imposes a rigorous framework including a twelve-month maximum duration, specific notice periods, a right-to-counsel disclosure, and geographic reasonableness. Furthermore, noncompetes are strictly prohibited for certain populations, including non-exempt employees under the FLSA, undergraduate or graduate interns, and any employee terminated without cause or laid off. These are statutory prerequisites; if the foundation fails these threshold tests, the question of business necessity never even reaches the court.
In the life sciences sector, where companies scale quickly and the stakes of talent departures are high, restrictive covenant strategies often fall behind the pace of business. Noncompetes may exist in a legacy file, but they are rarely audited for compliance with the shifting reality of federal and state law. The risk is hidden until a departure, a financing event, or a diligence cycle forces a review. At that point, discovery of an unenforceable agreement is a strategic liability that can complicate intellectual property protection and investor confidence.
The objective for leadership is not merely document review but the validation of an enforceable restrictive covenant framework. This requires a precise inventory to distinguish between noncompetes, confidentiality agreements, and invention assignments. It requires testing whether every restricted role actually has a defensible link to a protectable interest. And it requires confirming that the consideration provided meets a standard of sufficiency that can withstand judicial review.
Conducting this audit in partnership with Massachusetts employment counsel ensures that the findings are protected and the remediation is strategic. Waiting for a dispute to surface is now the highest-risk posture an organization can take. The current environment demands a move toward a more sophisticated, role-based strategy that reflects both the nuances of Massachusetts law and the priorities of federal regulators.
Technical Addendum: The "Protectable Interest" and Reformed Scope Standards While the Massachusetts Noncompetition Agreement Act, M.G.L. c. 149, § 24L, provides the skeletal framework for enforceability, the "protectable interest" standard remains the primary field of litigation. Under the statute, a noncompete is only valid to protect trade secrets, confidential information, or goodwill. It does not protect against ordinary competition or the general skill and knowledge an employee acquires on the job. Consequently, a blanket assertion of "access to sensitive data" is rarely sufficient for high-level enforcement; the connection between the specific role and the protectable asset must be defensible. Furthermore, Massachusetts founders should not rely on judicial "blue-penciling" (reformation) to cure overreach. While courts have the discretion to reform an overbroad agreement, they also retain the power to void an unreasonable restraint in its entirety. For the scaling life sciences organization, the most durable protection is a noncompete drafted to the narrowest defensible scope from the outset.
References: Federal Trade Commission Act, 15 U.S.C. § 45; Massachusetts Noncompetition Agreement Act, M.G.L. c. 149, § 24L; FTC Chairman Ferguson, Noncompete Warning Letters (2025); FTC Strategic Plan FY 2026-2030; Boston Beer Company Litigation, Case No. 1:25-cv-13618 (D. Mass. 2025); Cynosure LLC v. Reveal Lasers, LLC, Civ. No. 22-11176 (D. Mass. 2022).
Found this insight valuable? Share it with your network.
Disclaimer
The insights shared here are drawn from our work advising life sciences organizations on human capital strategy, compensation architecture, and workforce compliance. While we provide strategic HR advisory services to our clients, the content of this article is intended for general informational purposes and should not be construed as legal advice. Regulatory and market conditions evolve; organizations should consult qualified legal counsel before making specific employment or compliance decisions. For guidance tailored to your organization, contact our team.